{
    "ticker": "HUMA",
    "name": "Humacyte, Inc.",
    "description": "Humacyte, Inc. is a pioneering biotechnology company focused on developing and commercializing human acellular vessels (HAVs) for various medical applications. Founded in 2004 and headquartered in Durham, North Carolina, Humacyte aims to transform the treatment of vascular disease with its innovative products that can be used in traumatic injuries, dialysis, and reconstructive surgeries. The company's flagship product, the Humacyl, is an off-the-shelf, bioengineered blood vessel designed to mimic the structure and function of natural blood vessels while circumventing the issues of rejection and thrombosis associated with traditional grafts. Humacyte's mission is to improve the quality of life for patients suffering from vascular diseases and to provide surgeons with reliable, ready-to-use solutions. The company is also engaged in expanding its technology platform to address other unmet medical needs, leveraging its expertise in regenerative medicine and tissue engineering. As Humacyte continues to progress through clinical trials and regulatory approvals, it is poised to make significant contributions to the field of regenerative medicine and improve patient outcomes across various medical specialties.",
    "industry": [
        "Biotechnology",
        "Medical Devices"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "2004",
    "website": "https://www.humacyte.com",
    "ceo": "Carrie Cox",
    "social_media": {
        "twitter": "https://twitter.com/humacyte",
        "linkedin": "https://www.linkedin.com/company/humacyte/"
    },
    "investor_relations": "https://investors.humacyte.com",
    "key_executives": [
        {
            "name": "Carrie Cox",
            "position": "CEO"
        },
        {
            "name": "Michael A. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Vascular Products",
            "products": [
                "Humacyl"
            ]
        }
    ],
    "seo": {
        "meta_title": "Humacyte, Inc. | Innovating Vascular Solutions",
        "meta_description": "Explore Humacyte, Inc., a leader in biotechnology focused on human acellular vessels for vascular disease treatment. Learn about their innovative solutions and mission.",
        "keywords": [
            "Humacyte",
            "Biotechnology",
            "Vascular Products",
            "Medical Devices",
            "Regenerative Medicine",
            "Humacyl"
        ]
    },
    "faq": [
        {
            "question": "What is Humacyte known for?",
            "answer": "Humacyte is known for developing human acellular vessels for vascular applications."
        },
        {
            "question": "Who is the CEO of Humacyte?",
            "answer": "Carrie Cox is the CEO of Humacyte, Inc."
        },
        {
            "question": "Where is Humacyte headquartered?",
            "answer": "Humacyte is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "What are Humacyte's main products?",
            "answer": "Humacyte's main product is Humacyl, a bioengineered blood vessel."
        },
        {
            "question": "When was Humacyte founded?",
            "answer": "Humacyte was founded in 2004."
        }
    ],
    "competitors": [
        "SNY",
        "ABT",
        "ISRG"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MDT",
        "GILD"
    ]
}